ASCENDIS PHARMA A/S (ASND)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$270.56-0.21%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ASND
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
No current thesis-health read is available for this company.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -17.0% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
Why it matters: This report can change prices and profits in the drug industry.
Watch forPPI shows a decrease, suggesting lower input costs for ASCENDIS PHARMA.
Also watch forPPI is rising, which means higher costs for ASCENDIS PHARMA.
Why it matters: A drop in revenue growth signals a potential slowdown in the healthcare sector. This could impact investor confidence in ASCENDIS PHARMA.
Worry ifQ2 revenue growth reported below the sector median of recent years.
Less concerning ifQ2 revenue growth remains at or above the sector median.
Why it matters: A drop in revenue growth could signal a slowdown in the healthcare sector. This affects all companies, including Ascendis.
Worry ifHealthcare sector revenue growth drops below its median rate of 5%.
Less concerning ifHealthcare sector revenue growth remains above its median rate of 5%.
Why it matters: If revenue growth speeds up, it may mean good news for ASCENDIS PHARMA.
Supportive ifHealthcare sector revenue growth speeds up again, reaching above 9%.
Worry ifHealthcare sector revenue growth slows down, dropping below 9%.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$114 on $10,000 · ±1.1% | How much price usually moves either way. |
| Bad day | $346 loss on $10,000 · 3.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $1,762 loss on $10,000 · 17.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: CPI impacts how much consumers spend and can affect ASCENDIS PHARMA's market.
Watch forCPI is down. This means lower inflation and possibly better spending by consumers.
Also watch forCPI is up. This means higher inflation and possible pressure on consumer spending.